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Background 
• Excluding acute coronary syndrome (ACS) in primary care is a diagnostic challenge for general practitioners (GPs). 
• Because of the severity of ACS, referral rates to secondary care are high.  
• However, in only 14-16% of these patients a cardiac origin is found to cause the symptoms. 
• This poses a burden on both a hospital’s treatment capacity as well as on the healthcare budget. 
 
Point of care testing (POCT) of cardiac markers might improve the certainty with which ACS can be ruled out at the GP’s office and 
reduce referral rates to secondary care. 
 
Objective: 
Estimate the minimum sensitivity and specificity of the GP’s clinical assessment combined with POCT (POCT strategy) that is required 
to be cost-effective compared to clinical assessment by the GP only (non-POCT strategy). 
A health economic model was developed, investigating the costs and health benefits of the two strategies: 
• Data were obtained from the Dutch Healthcare Authority (NZA), the cost manual by Hakkaart-van Roijen, 20101, and from a 
systematic search of published medical literature. 
• Health benefit was expressed as health-related quality of life, i.e. QALYs. 
• Sensitivity and specificity for a GP’s clinical assessment for ACS (non-POCT strategy) is set at 88.3% and 72.2% respectively2. 
• Willingness To Pay Threshold: POCT is considered cost-effective when the POCT strategy costs less than €30,000 per QALY 
gained compared to the non-POCT strategy. 
 
Threshold analysis:  
• Goal: to identify the minimum combinations of sensitivity and specificity that are required for the POCT strategy to be considered 
cost-effective compared to the non-POCT strategy. 
• Following this, the expected effect of those combinations on health outcomes will be investigated. 
POCT Costs > €30.000/QALY and/or results in QALY loss 
POCT saves money and results in QALY gain 
POCT Costs ≤ €30.000 
/QALY but results in 
QALY gain  
Findings: 
• A higher specificity decreases the number of false-positive test results. 
• This is expected to reduce the number of false-positive referrals, 
thereby decreasing costs. 
• A higher sensitivity might decrease the number of false-negative test results. 
• This might prevent inadvertent discharge of patients, thereby 
improving the quality of care (QALY gain). 
Effect of performance of the POCT strategy on health outcomes (per 100,000 GP consultations). 
Methods 
Results 
Conclusion and Discussion 
The use of a POCT cardiac marker in primary care might: 
• Improve both the rule-out and rule-in of ACS at the GP, thereby decreasing referral rates and contribute to decreasing healthcare 
costs as well as improving quality of care.  
• Additional research is necessary to investigate the subgroup of patients with suspected ACS for which GPs consider POCT cardiac 
markers (e.g. troponin) helpful in their clinical decision-making. 
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  Performance POCT strategy 
False-negative 
test results 
avoided 
False-positive 
test results 
avoided 
Mortality  
cases avoided 
New heart 
failure cases 
avoided 
  Sensitivity 97%, Specificity 95%  331 21,883  33  69 
  Sensitivity 97%, Specificity 75%  329   2,644  33  72 
  Sensitivity 85%, Specificity 70% -127  -2,161 -26 -21 
  Sensitivity 85%, Specificity 89% -123 16,139 -25 -23 
Net health benefit. This graph shows the net health benefit for the 
POCT strategy compared to the non-POCT strategy. Green indicates 
combinations of sensitivity and specificity at which the POCT-strategy 
is expected to be cost-effective at a WTP of €30,000/QALY, while red 
indicates the POCT strategy to be cost-ineffective at this WTP. The 
black dot represents the non-POCT strategy (base case). 
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